trending Market Intelligence /marketintelligence/en/news-insights/trending/mm7czH-kDc45D8XUnXATBg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ionis CEO to become executive chairman in 2020

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ionis CEO to become executive chairman in 2020

Ionis Pharmaceuticals Inc. said founder and CEO Stanley Crooke will transition to executive chairman of the company's board of directors, effective January 2020.

Brett Monia, who has been COO for the previous year and a founding member of Carlsbad, Calif.-based Ionis, will take over from Crooke as CEO.

Crooke will continue to be in charge of board affairs and will provide strategic advice, as well as participate in the scientific activities of the company.

Ionis develops RNA-targeted therapies for genetic diseases such as spinal muscular atrophy, transthyretin amyloidosis and familial chylomicronemia syndrome.